A-Synaptic Pharma

A-Synaptic Pharma is an early-stage biotech focused on revolutionizing cannabinoid therapeutics through its advanced transdermal 'liquid needle' delivery platform, GT4. The company's technology aims to overcome the challenges of delivering lipophilic cannabinoid molecules through the skin, offering precise dosing, rapid absorption, and avoidance of first-pass liver metabolism. Its lead development program targets pediatric epileptic seizures, and it has completed a human bioavailability study in Canada, positioning it to pursue clinical development in the United States.

GT4, a patented 'liquid needle' transdermal emulsion technology designed for the active delivery of lipophilic cannabinoid molecules through the skin for systemic or local tissue targeting. It uses penetration agents, basement membrane disruptors, and vasodilators in a cream/gel formulation to enable rapid, precise dosing.

A-Synaptic competes in the cannabinoid pharmaceutical and advanced transdermal delivery sectors. It faces competition from companies developing oral cannabinoid drugs (e.g., Jazz Pharmaceuticals' Epidiolex) and other drug delivery firms. Its differentiation lies in its specific, patented 'liquid needle' technology for cannabinoids, aiming for superior pharmacokinetics and dosing control.